Drug treatment rather than observation may delay disease progression and extend survival in persons with high-risk smoldering multiple myeloma, according to recent study results.
FDA-related news items of relevance from the month of June, 2013.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.
Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial
Multiple myeloma patients experience high response rates when treated with a drug regimen consisting of 3 drugs, according to data presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|